Podcasts about Koch Institute

A Biomarker Dialogue Between Patient and Scientist HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Marc Muskavitch, PhD, ALK+ & Zachary Rogers, PhD, Research Fellow, Koch Institute at MIT This episode features a powerful conversation between two scientists, one now navigating life as a Stage 4 ALK+ lung cancer patient. Most lung cancer patients only learn … Continue reading Living with ALK+: Diagnosis, Treatment, & Hope →

Professor Dane Wittrup attended the University of New Mexico as an undergraduate, graduating Summa Cum Laude with a Bachelors in Chemical Engineering in June, 1984. Wittrup went on to attend the California Institute of Technology in Pasadena, where he worked with Prof. James Bailey on flow cytometry and segregated modeling of recombinant populations of Saccharomyces cerevisiae. After obtaining his Ph.D. in Chemical Engineering with a minor in Biology in 1988, he spent a brief time working at Amgen before becoming an Assistant Professor of Chemical Engineering at the University of Illinois at Urbana-Champaign in 1989. He moved to the Massachusetts Institute of Technology in September of 1999, where he is now the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, in addition to working with the Koch Institute as the Associate Director for Engineering.w/ Special Guest Host: Jacob Becraft - Co-Founder & CEO @ Strand TherapeuticsJake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics, and serves on its Board of Directors. Together with colleagues at MIT's renowned Synthetic Biology Center, he led the development of the world's first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, the Boston Business Journal, and BioCentury, among others, for his vision and mission at Strand of applying this unique platform for real world disease applications. He has also been the recipient of prestigious national and international awards for his scientific and entrepreneurial achievements, including the Barry Goldwater Scholarship and Excellence in Education Award, the Andrew Viterbi Fellowship of MIT, Amgen Fellowship, and the Bristol-Myers Squibb 2018 Golden Ticket for recognition of Strand as an innovative startup. Beyond his work at Strand, Jake's broader interests span synthetic biology, biologically engineered organism-machine interfaces, and the intersection of tech and biotech methodologies. He is an advocate among the life science entrepreneurial ecosystem for supporting young founders in biotech entrepreneurship. Currently, he serves on the advisory board of Starlight Ventures, an early stage venture firm, and also serves on the Executive Board of Public Health United, a non-profit focused on helping scientists better communicate their research for maximum impact. Previously, he served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. Jake received his Ph.D. in Biological Engineering and Synthetic Biology from MIT and his B.S. in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. He is an author or inventor on numerous high profile publications, patents and white papers, including in top tier journals such as Nature Chemical Biology and PNAS.Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Darrell Irvine obtained an Honors Bachelor's degree in engineering physics from the University of Pittsburgh. As a National Science Foundation graduate fellow, he then studied Polymer Science at MIT. Following completion of his PhD, he was a Damon Runyon-Walter Winchell postdoctoral fellow in immunology at the Beckman Center for Molecular and Genetic Medicine. He is presently a professor at the Massachusetts Institute of Technology and an investigator of the Howard Hughes Medical Institute. He is also an Associate Director for the Koch Institute and serves on the steering committee of the Ragon Institute of MGH, MIT, and Harvard. Irvine is the founder of Elicio Therapeutics, Strand Therapeutics, and Ankyra Therapeutics. He serves on the Scientific Advisory Boards of the MGH Cancer Center, the University of Toronto Medicine by Design Consortium, Venn Therapeutics, Alloy Therapeutics, Jupiter Therapeutics, Parallel Bio, Surge Therapeutics, and Gensaic Therapeutics.w/ Special Guest Host: Jacob Becraft - Co-Founder & CEO @ Strand TherapeuticsJake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics, and serves on its Board of Directors. Together with colleagues at MIT's renowned Synthetic Biology Center, he led the development of the world's first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, the Boston Business Journal, and BioCentury, among others, for his vision and mission at Strand of applying this unique platform for real world disease applications. He has also been the recipient of prestigious national and international awards for his scientific and entrepreneurial achievements, including the Barry Goldwater Scholarship and Excellence in Education Award, the Andrew Viterbi Fellowship of MIT, Amgen Fellowship, and the Bristol-Myers Squibb 2018 Golden Ticket for recognition of Strand as an innovative startup. Beyond his work at Strand, Jake's broader interests span synthetic biology, biologically engineered organism-machine interfaces, and the intersection of tech and biotech methodologies. He is an advocate among the life science entrepreneurial ecosystem for supporting young founders in biotech entrepreneurship. Currently, he serves on the advisory board of Starlight Ventures, an early stage venture firm, and also serves on the Executive Board of Public Health United, a non-profit focused on helping scientists better communicate their research for maximum impact. Previously, he served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. Jake received his Ph.D. in Biological Engineering and Synthetic Biology from MIT and his B.S. in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. He is an author or inventor on numerous high profile publications, patents and white papers, including in top tier journals such as Nature Chemical Biology and PNAS.Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

In this episode Jonathan Gertler, Back Bay's CEO and Managing Partner, sits down with Dr. Peter Bak, Managing Director at Back Bay, to discuss Dr. Bak's latest article in STAT News and to talk about the world of anti-infectives.Dr. Bak has more than ten years of expertise in infection and treatment. He began his research at Dartmouth Medical School and later continued at MIT, where he was an American Cancer Society Postdoctoral Fellow at the Koch Institute of Integrative Cancer Research.Topics include:-The landscape of antiinfectives, antimicrobials & antifungals -How commercial dynamics drive clinical unmet need -The role the pandemic played on development & investments -The deployment of cell therapies for viral diseases -Foundation support for anti-infectives -“Push incentives” to usher therapies into commercial stagesLink to Dr. Peter Bak's published article in STAT News, “Investment in antimicrobials was up in 2020, but much work remains," https://www.statnews.com/2021/04/28/investment-antimicrobials-uptick-2020-much-work-remains/

Dr Bill Nelson speaks with Tyler Jacks, the President of Break Through Cancer, a collaborative partnership between The Johns Hopkins Kimmel Cancer Center, The Dana Farber Cancer Institute, The Koch Institute for Integrative Cancer Research at MIT, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center designed with the goal of curing the most lethal cancers.

Professor Paula Hammond is a pioneer in chemical engineering, as well as the Department Head of Chemical Engineering at MIT and a faculty member at the Koch Institute for Integrative Cancer Research. Her interdisciplinary work focuses on nanoparticle technology with wide-ranging applications. Hammond’s work has and will greatly shape the future of drug delivery, with her nanoparticles able to target hard-to-treat cancers like ovarian cancer. Using her nanoparticle approach, she is currently developing a way to regenerate bone and treat osteoarthritis. She is proud of her visibility within her field, both as a testament to her passion to create new solutions to big problems and to show African Americans and women that their voices are both necessary and important in scientific research. Music by Kevin MacLeod licensed under CC BY 4.0.

How can cancer and cancer cells be understood through the lens of cellular metabolism, and what insights can be gained into various forms of treatment? Many studies suggest that metabolic changes and the environment in which the cells inhabit can significantly impact how they function. Listen in to learn: How cancer cells are affected by oxygen availability Some often-overlooked benefits of Chemotherapy How cellular metabolism and pathways can affect the development of cancer cells Oncologist and cancer researcher at the Koch Institute at MIT, Dr. Matthew Vander Heiden, shares his research experience and some surprising cellular processes that can dramatically impact cancer cells. Dr. Vander Heiden sheds light on the Warburg effect, which describes how cancer cells tend to uptake glucose and ferment it rather than burning it in respiration. The fermentation of glucose rather than respiration is revealed to be how FDG PET scans function by differentiating cancer cells that use more sugar and show up highlighted on the scan. The fermentation process ultimately produces ATP and lactate to fuel the cancer cell. Alongside development pathways for the cells, oxygen is also a limiting factor on cancer cells, and the lack or surplus will encourage particular pathways to be used. Due to the availability of particular nutrients in different regions of the body, it is also thought that an individual's diet can impact the development of cancer cells. This is explained the clustering and absorption of those nutrients at different concentrations throughout the body. For more information, visit https://ki.mit.edu. Episode also available on Apple Podcasts: apple.co/30PvU9C

Dr Bill Nelson and Dr Elizabeth Jaffee discuss the creation of Break Through Cancer, a new collaborative partnership between The Johns Hopkins Kimmel Cancer Center, The Dana Farber Cancer Institute, The Koch Institute for Integrative Cancer Research at MIT, MD Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center that will help accelerate research, clinical trials, and new treatments for the most lethal cancers. To learn more about Break Through Cancer, visit breakthroughcancer.org.

Ben Azadi reveals 3 ways to practice fasting for weight loss. Discover beginner and advanced strategies designed to teach you how to lose weight with fasting. You'll learn how to break a fast without gaining weight, a go to intermittent fasting schedule, and the benefits of block extended fasting for 72 hours.

In this episode, I chat with Dr. Padmini Pillai, an Immunoengineer and CRI Irvington Postdoctoral Fellow in the legendary Langer Lab at MIT's Koch Institute for Integrative Cancer Research. Padmini completed her undergrad at Regis College and then worked as a Research Technician in Prof. Charles Serhan's lab at Harvard Medical School before earning her PhD in Immunology at the renowned Iwasaki Lab at Yale. Padmini is also a very accomplished musician who has performed at Carnegie Hall, Kennedy Center, Newport Jazz Festival, singing backup for Grammy Award-winning singer Angelique Kidjo!! A Delegate to the American Academy of Achievement and a former Convergence Scholar at MIT, Padmini works on designing diverse biomaterial strategies to boost antitumor immunity, resolve chronic inflammatory disease, and elucidate pathways involved in allergic inflammation. We indulge in a terrific conversation on her fascinating journey in science; incredible inspirations like her parents and older brother, themselves accomplished academicians, who fostered her interest in science; fantastic mentors like Bob Langer and Akiko Iwasaki who've guided her along; her groundbreaking research that's on the frontiers of the intersection of engineering and immunology; a life-changing experience during grad school battling a rare and deadly liver disorder, Acute Intermittent Porphyria; deep interest in music, a familial trait, and how it has transformed her as a person and scientist; making science a more equitable, diverse, and inclusive space; and many more things!!

In this episode, Ed Boyden joins us to discuss his research at MIT and how an imaging technology developed by Boyden and his colleagues is applicable to type 1 diabetes researchers. Dr. Boyden leads the Synthetic Neurobiology Group, which develops tools for analyzing and repairing complex biological systems such as the brain, and applies them systematically to reveal ground truth principles of biological function as well as to repair these systems. He co-directs the MIT Center for Neurobiological Engineering, which aims to develop new tools to accelerate neuroscience progress, and is a faculty member of the MIT Center for Environmental Health Sciences, Computational & Systems Biology Initiative, and Koch Institute.To learn more about Dr. Boyden's research follow the link below:Synthetic Neurobiology Group

Dr. Stephanie Seneff's Story Dr. Stephanie Seneff is a Senior Research Scientist at MIT's Computer Science and Artificial Intelligence Laboratory in Cambridge, Massachusetts, USA. She has a BS degree from MIT in biology and a PhD from MIT in electrical engineering and computer science. Her recent interests have focused on the role of toxic chemicals and micronutrient deficiencies in health and disease, with a special emphasis on the pervasive herbicide, Roundup, and the mineral, sulfur. She has authored over three dozen peer-reviewed journal papers on these topics. You'll Learn: Why glyphosate is a bigger problem than any virus How glyphosate undermines healthy cellular function Why the toxicity of glyphosate leads to a "viral" explosion in the body What the virus is ACTUALLY doing in your body Which microbial pathways are disrupted by gylphosate... ...and how this destroys our health. More reasons why Terrain Theory supercedes Germ Theory ...and much, much more. Stephanie Seneff brings a unique scientific angle to the convid discussion, highlighting some issues you aren't likely to hear about anywhere else. Please subscribe, drop a review, and share this information widely. Thanks in advance for supporting the nascent emergence of deep human self-awareness - and the FREEDOM this will bring us all. Special Guest: Dr. Stephanie Seneff.

#015 Terry McGuire is the Co-founder and General Partner of Polaris Partners. Polaris Partners has a portfolio including Adimab, Akamai (IPO), Acceleron (IPO), and Ironwood (IPO).  Before starting his own fund, he spent seven years at Burr, Egan, Deleage, & Co. His investments are focused on early-stage medical and information technology companies. He was on the Forbes Midas List of the top 100 tech investors several times. He received the Massachusetts Society for Medical Research Award and the Albert Einstein Award for Outstanding Achievements in Life Sciences (awarded by Harvard and the City of Jerusalem). He is chairman emeritus of the National Venture Capital Association and chairman of the Global Venture Capital Congress. He holds an engineering degree from Dartmouth College, an MBA from Harvard Business School, and a BS in physics and economics from Hobart College. He is on the board of MIT’s David H. Koch Institute for Integrative Cancer Research, the Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and the Healthcare Initiative Advisory Board (HBS). He also chairs the board of the Thayer School of Engineering at Dartmouth College. https://www.SmartVenturePod.com IG/Twitter/FB @GraceGongGG LinkedIn:@GraceGong Join the SVP fam with your host Grace Gong. In each episode, we are going to have conversations with some of the top investors, super star founders, as well as well known tech executives in the silicon valley. We will have a coffee chat with them to learn their ways of thinking and actionable tips on how to build or invest in a successful company.

#014 Terry McGuire is the Co-founder and General Partner of Polaris Partners. Polaris Partners has a portfolio including Adimab, Akamai (IPO), Acceleron (IPO), and Ironwood (IPO).  Before starting his own fund, he spent seven years at Burr, Egan, Deleage, & Co. His investments are focused on early-stage medical and information technology companies. He was on the Forbes Midas List of the top 100 tech investors several times. He received the Massachusetts Society for Medical Research Award and the Albert Einstein Award for Outstanding Achievements in Life Sciences (awarded by Harvard and the City of Jerusalem). He is chairman emeritus of the National Venture Capital Association and chairman of the Global Venture Capital Congress. He holds an engineering degree from Dartmouth College, an MBA from Harvard Business School, and a BS in physics and economics from Hobart College. He is on the board of MIT’s David H. Koch Institute for Integrative Cancer Research, the Arthur Rock Center for Entrepreneurship at Harvard Business School (HBS), and the Healthcare Initiative Advisory Board (HBS). He also chairs the board of the Thayer School of Engineering at Dartmouth College. https://www.SmartVenturePod.com IG/Twitter/FB @GraceGongGG LinkedIn:@GraceGong Join the SVP fam with your host Grace Gong. In each episode, we are going to have conversations with some of the top investors, super star founders, as well as well known tech executives in the silicon valley. We will have a coffee chat with them to learn their ways of thinking and actionable tips on how to build or invest in a successful company.

Feels like this one speaks for itself?  Basically we somehow got an hour with Cedric Maxwell, Celtics legend talking about all things hoops - ranging from the Celtics' title hopes to life on the road as a player...and life on the road as a..."player" wink wink. This took us down a path of his personal groupie stories and everyone's favorite recreational substance - that's right, crack cocaine!    We also got his side of the story on the Finals MVP watch and got a glimpse at the shiny little Seiko. Finally we talked about how the modern day sandwich became his favorite catchphrase while calling games, how he'd like to be represented on The Nashua Garden sandwich menu, and whether or not he could work in a Morse Code Podcast shoutout mid telecast.   All the credit and shoutout goes to Cedric as well as previous guest Nick Gelso of CLNS for setting this one up, so please follow both Cedric and Nick on their respective platforms below:  Cedric:  - @cedricmaxwell81 on Twitter - @therealcedricmaxwell on IG - Celtics Color Commentary on 98.5 SportsHub         - https://podcasts.apple.com/us/podcast/the-cedric-maxwell-podcast/id1461676761  Nick Gelso, CEO and Founder of CLNS Media:  - @CLNS_Nick on Twitter for his account, or @CLNSMedia for the company account - Contributor at CelticsBlog - Podcast Mentor and Adviser at the Koch Institute, nickg@clnsmedia.com  As always, please follow us on Instagram @themorsecodepod, our personal handles @CambodianPrince_ & @DJMorse126 and like/subscribe to this YouTube channel and our podcast at http://aliasconnect.co/morsecodepod

In this episode Tim chats with Phil Sharp, Nobel laureate, Institute Investigator at MIT and member of the Biology Department as well as the Koch Institute. Phil confronted the question of how large protein complexes assemble inside of cells nearly 30 years ago, but had no way to address it at that time. He tells […]

Professor Michael Cima chats with host Charlie Webb about his Drug and Medical device development course offered through the xPRO program at MIT. The course goals are to help participants gain a “big picture” perspective of the entire drug and medical device development process, from day one strategic planning through product commercialization. Also, students will understand the critical interplay between strategy and development and how they affect each other. This online program helps you explore the process of discovering, developing, testing, and bringing a medical product to market. Guest Description:Dr. Michael J. Cima is a Professor of Materials Science and Engineering at the Massachusetts Institute of Technology and has an appointment at the David H. Koch Institute for Integrative Cancer Research. He earned a B.S. in chemistry in 1982 (phi beta kappa) and a Ph.D. in chemical engineering in 1986, both from the University of California at Berkeley. Prof. Cima joined the MIT faculty in 1986 as an Assistant Professor. He was promoted to full Professor in 1995. He was elected a Fellow of the American Ceramics Society in 1997. Prof. Cima was elected to the National Academy of Engineering in 2011. He now holds the David H. Koch Chair of Engineering at MIT. He was appointed faculty director of the Lemelson-MIT Program in 2009 which is a program to inspire youth to be inventive and has a nationwide reach.Prof. Cima is author or co-author of over two hundred and fifty peer-reviewed scientific publications, fifty-eight US patents, and is a recognized expert in the field of materials processing. more on his Bio https://cima-lab.mit.edu/people/cimaLearn more about the Drug and Medical device development course.

Dr. Rameen Shakur is a Jansen Fellow in Cardiology and Personalized Medicine at the Koch Institute for Integrative Science at MIT, and the Founder of the medical device and algorithm company Cambridge Heartwear Ltd.

How much does a cancer cell weigh? And why does it matter? As cancer cells die, they change their weight in a matter of hours. A new device called the Suspended Microchannel Resonator (SMR) is a new technology that can measure a small change in the weight of a single cancer cell. The SMR machine can detect this change and tell whether a cancer cell has died of "natural causes" or if it was killed by a cancer drug. This allows rapid assessment of whether an individual patient is responding to a cancer treatment or not. This wraps together everything about a cancer patient (such as their myeloma genetics, environmental and other biological factors) and analyzes the response to treatment, making it truly personalized medicine.  A company called Travera is now working to commercialize this technology developed in the Manalis Laboratory in the Koch Institute for Integrative Cancer Research at MIT. It was recently tested in multiple myeloma in a small study at Dana Farber. Learn more about this fascinating technology that may create the first universal biomarker for cancer in this interview with Traver's CEO, Clifford Reid, PhD.  Thank you to our episode sponsor, GSK. 

In this episode, we turn to another set of democratic institutions: faith-based organizations and alliances. Alvin Edwards is not only a former mayor of Charlottesville; he is the pastor of Charlottesville’s largest African American church and he founded the Charlottesville Clergy Collective, which includes Charlottesville synagogue, Catholic church, and mosque. As you’ll hear him describe, the collective played a significant role in designing the community response to the alt-right invasions of 2017 and afterward. Sarah Ruger runs Free Expression programs at the Charles Koch Institute. It has been surprising to some that this podcast includes a partnership between organizations like the Anti-Defamation League, the Ford Foundation and conservative organizations like the Charles Koch Institute. She speaks about the power of alliances in working against extremism, and what brought the libertarian Koch Institute to this cause.

A complex task: strategies to tune altered transcription in cancer Please join us as we welcome MIT Professor Angela Koehler. Angela is the Goldblith Career Development Professor in Applied Biology in the Department of Biological Engineering at MIT and an intramural member of the David H. Koch Institute for Integrative Cancer Research at MIT. She is also an Institute Member of the Broad Institute and a Founding Member of the MIT Center for Precision Cancer Medicine. Her research group aims to discover and develop functional small-molecule probes of transcriptional regulators, including chromatin modifying enzymes and oncogenic transcription factors. Validated probes may be used to advance the understanding of transcription in development and disease. Selected probes may be developed into imaging agents, diagnostic tools, or therapeutic leads. Angela received her B.A. in Biochemistry and Molecular Biology from Reed College in 1997. There she worked under the guidance of Professor Arthur Glasfeld on structural and biochemical studies of proteins that recognize tRNA or DNA. In 2003, she received her Ph.D. in Chemistry from Harvard University where she worked with Professor Stuart Schreiber to develop novel technologies for identifying and characterizing interactions between proteins and small molecules. Upon graduation, she became an Institute Fellow in the Chemical Biology Program at the Broad Institute and a Group Leader for the NCI Initiative for Chemical Genetics.

Robert Langer is the David H. Koch Institute professor at the Massachusetts Institute of Technology. He also runs the Langer Lab and is co-founder of more than 40 biotech companies. His talk with Nature Biotechnology covers the death of his father, his experience teaching high school science and math, and the requirements for launching a successful biotech. See acast.com/privacy for privacy and opt-out information.

To celebrate the 15-year anniversary of the NNI, special anniversary episodes of the Stories from the NNI podcast series will showcase experts from academia, government, and industry. This inaugural anniversary episode features a conversation between Lisa Friedersdorf, Director of the National Nanotechnology Coordination Office, and Tarek Fadel, Assistant Director of the Marble Center for Cancer Nanomedicine at the Massachusetts Institute of Technology’s Koch Institute for Integrative Cancer Research. Lisa and Tarek discuss the NNI’s impact on the nanotechnology research and development landscape, take stock of compelling research advances enabled by the NNI, and share what excites them the most about nanotechnology. Closed captioning is available on YouTube. Find this episode here: https://www.youtube.com/watch?v=LMZWH1yvT78&t=2s Learn more about nanotechnology at www.nano.gov or email us at info@nnco.nano.gov. CREDITS Special thanks to Dr. Tarek Fadel Assistant Director Marble Center for Cancer Nanomedicine MIT Koch Institute for Integrative Cancer Research Music: Corporate Uplifting by Scott Holmes http://freemusicarchive.org/music/Scott_Holmes/Corporate__Motivational_Music/Corporate_Uplifting_1985 https://creativecommons.org/licenses/by-nc/4.0/legalcode Produced by: Dr. Mallory Hinks AAAS S&T Policy Fellow at NNCO Any opinions, findings, conclusions, or recommendations expressed in this podcast are those of the guest and do not necessarily reflect the views of the National Nanotechnology Coordination Office or United States Government. Additionally, mention of trade names or commercial products does not constitute endorsement or recommendation by any of the aforementioned parties. Any mention of commercial products, processes, or services cannot be construed as an endorsement or recommendation.

Hearing how one of the world’s leading researchers on genetically engineered mouse models rises to success from his or her beginnings is a valuable experience for anyone pursuing the path of biomedical research. Transnetyx CEO, Bob Bean, sits down and interviews individuals impacting the world of science to discover characteristics, disciplines, and memorable moments that have shaped them. In this episode, Bob had the privilege to interview one of cancer research’s pioneers. Tyler Jacks, Ph.D., Director of the Koch Institute for Integrative Cancer Research at MIT, shares his journey from early childhood, his amazing circle of influence, the power of mentorship, and shares invaluable wisdom from his long career to aspiring researchers.

Dr. Kathryn (Katie) Whitehead is an Assistant Professor in Chemical Engineering at Carnegie Mellon University where she also holds a courtesy appointment in Biomedical Engineering. Research in Katie’s lab group focuses on therapeutic drug delivery. Their goal is to make the process of drug delivery more efficient by sending medicine only to the specific parts of the body where they are needed. Katie is also working to create new precision medicines using RNA and DNA and to develop the drug delivery systems for these future medicines. Since she was a PhD student, Katie has been interested in gardening. She started with just a single tomato plant, and now she grows over 20 different varieties of heirloom tomatoes, as well as other vegetables, fruits, and berries. Katie received her bachelor’s degree in chemical engineering from the University of Delaware and her PhD in chemical engineering from the University of California, Santa Barbara. Afterwards, she conducted postdoctoral research in the Koch Institute for Integrative Cancer Research at MIT. Katie has received numerous awards and honors, including the DARPA Young Faculty Award, the DARPA Director’s Fellowship, the Controlled Release Society Capsugel/Pfizer Oral Drug Delivery Award, the Diabetes Technology Society Peterson Research Award, a UC Graduate Research and Education in Adaptive Biotechnology Fellowship, an NIH Ruth Kirschstein National Research Service Award Fellowship, the Kun Li Award for Excellence in Education, the Popular Science Brilliant 10 Award, and very recently the 2018 National Institutes of Health (NIH) Director’s New Innovator Award. She has also been named an MIT Technology Review Innovator Under 35 and the 2016 Young Innovator Award from Cellular and Molecular Bioengineering (CMBE). In our interview, Katie speaks more about her experiences in life and science.

Even the Koch Institute Has a Presidential Pardon List of Thousands of Prisoners (2:22) Kerry Shakaboona Marshall

Talk 6 - Uygana Tsedev from the Koch Institute talks about how biological engineering is used to find and image deeply embedded and difficult to reach tumors.